Parkinson’s disease is a wide-spread neurodegenerative
disorder with over 200,000 USA cases per year. The primary symptoms are loss of
control over muscle movements which get progressively worse with time. This
disease is caused by damage to dopaminergic neurons which leads to a lack of
dopamine in the brain. Although incurable, there are drugs that can delay the
progression of Parkinson’s. Because the drug action must occur within the
brain, any medicine applied must cross the blood-brain-barrier, a screen that
prevents most medicines from reaching the brain. Recently, researchers at
Yantai University and Shandong Luye Pharmaceutics utilized mal-PEG-PLGA
(Polyvivo AI109) and mPEG-PLGA (PolyVivo AK104) from PolySciTech (www.polyscitech.com) to generate
lactoferin-decorated nanoparticles for rotigotine delivery across the
blood-brain-barrier as a potential treatment for Parkinson’s disease. This
research holds promise to halt the progress of this lethal disease. Read more: Yan
X, Xu L, Bi C, Duan D, Chu L, Yu X, Wu Z, Wang A, Sun K “Lactoferrin-modified
rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based
drug biodistribution, pharmacodynamics, and neuroprotective effects” International
Journal of Nanomedicine, 9 January 2018 Volume 2018:13 Pages 273—281 https://www.dovepress.com/lactoferrin-modified-rotigotine-nanoparticles-for-enhanced-nose-to-bra-peer-reviewed-fulltext-article-IJN
“Introduction: Efficient delivery of rotigotine into the
brain is crucial for obtaining maximum therapeutic efficacy for Parkinson’s
disease (PD). Therefore, in the present study, we prepared lactoferrin-modified
rotigotine nanoparticles (Lf-R-NPs) and studied their biodistribution,
pharmacodynamics, and neuroprotective effects following nose-to-brain delivery
in the rat 6-hydroxydopamine model of PD. Materials and methods: The biodistribution
of rotigotine nanoparticles (R-NPs) and Lf-R-NPs after intranasal
administration was assessed by liquid extraction surface analysis coupled with
tandem mass spectrometry. Contralateral rotations were quantified to evaluate
pharmacodynamics. Tyrosine hydroxylase and dopamine transporter
immunohistochemistry were performed to compare the neuroprotective effects of
levodopa, R-NPs, and Lf-R-NPs. Results: Liquid extraction surface analysis
coupled with tandem mass spectrometry analysis, used to examine rotigotine
biodistribution, showed that Lf-R-NPs more efficiently supplied rotigotine to
the brain (with a greater sustained amount of the drug delivered to this organ,
and with more effective targeting to the striatum) than R-NPs. The
pharmacodynamic study revealed a significant difference (P<0 .05="" 6-hydroxydopamine-induced="" alleviated="" and="" between="" biodistribution="" brain="" conclusion:="" contralateral="" deliver="" disease="" dopaminergic="" drug="" effects="" efficacy.="" efficiently="" enhancing="" findings="" for="" furthermore="" have="" in="" keywords:="" lactoferrin-modified="" lf-r-nps="" might="" model="" more="" nanoparticles="" neurodegeneration="" neuroprotective="" nigrostriatal="" nose="" o:p="" of="" our="" parkinson="" pd.="" pharmacodynamics="" potential="" r-nps.="" rat="" rats="" rotations="" rotigotine="" s="" show="" significantly="" that="" the="" therapeutic="" thereby="" therefore="" those="" to="" treated="" treatment="" with="">0>
No comments:
Post a Comment